# Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

> **NCT04379635** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **BeiGene** · enrollment: 453 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Cisplatin injection
- **DRUG:** Paclitaxel injection
- **DRUG:** Pemetrexed Disodium
- **DRUG:** Placebos
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04379635
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-29
- **Primary completion:** 2023-08-21
- **Final completion:** 2027-03-31
- **Target enrollment:** 453 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04379635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04379635, "Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04379635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*